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Abstract
Background: Oral Squamous Cell Carcinoma (OSCC) is a major cause of cancer death worldwide, which is mainly
due to recurrence leading to treatment failure and patient death. Histological status of surgical margins is a
currently available assessment for recurrence risk in OSCC; however histological status does not predict recurrence,
even in patients with histologically negative margins. Therefore, molecular analysis of histologically normal
resection margins and the corresponding OSCC may aid in identifying a gene signature predictive of recurrence.
Methods: We used a meta-analysis of 199 samples (OSCCs and normal oral tissues) from five public microarray
datasets, in addition to our microarray analysis of 96 OSCCs and histologically normal margins from 24 patients, to
train a gene signature for recurrence. Validation was performed by quantitative real-time PCR using 136 samples
from an independent cohort of 30 patients.
Results: We identified 138 significantly over-expressed genes (> 2-fold, false discovery rate of 0.01) in OSCC. By
penalized likelihood Cox regression, we identified a 4-gene signature with prognostic value for recurrence in our
training set. This signature comprised the invasion-related genes MMP1, COL4A1, P4HA2, and THBS2. Over-
expression of this 4-gene signature in histologically normal margins was associated with recurrence in our training
cohort (p = 0.0003, logrank test) and in our independent validation cohort (p = 0.04, HR = 6.8, logrank test).
Conclusion: Gene expression alterations occur in histologically normal margins in OSCC. Over-expression of the 4-
gene signature in histologically normal surgical margins was validated and highly predictive of recurrence in an
independent patient cohort. Our findings may be applied to develop a molecular test, which would be clinically
useful to help predict which patients are at a higher risk of local recurrence.
Keywords: oral squamous cell carcinoma, surgical resection margins, global gene expression profiling, prognostic
signature, recurrence
Background
Oral Squamous Cell Carcinoma (OSCC) accounts for
24% of all head and neck cancers [1]. Currently available
protocols for treatment of OSCCs include surgery,
radiotherapy and chemotherapy. Complete surgical
resection is the most important prognostic factor [2],
since failure to completely remove a primary tumor is
the main cause of patient death. Accuracy of the resec-
tion is based on the histological status of the margins,
as determined by microscopic evaluation of frozen sec-
tions. Presence of epithelial dysplasia or tumor cells in
the surgical resection margins is associated with a signif-
icant risk (66%) of local recurrence [3]. However, even
with histologically normal surgical margins, 10-30% of
OSCC patients will still have local recurrence [4], which
may lead to treatment failure and patient death.
Since histological status of surgical resection margins
alone is not an independent predictor of local recur-
rence [5], histologically normal margins may harbor
underlying genetic changes, which increase the risk of
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dies have identified genetic alterations in surgical resec-
tion margins in head and neck squamous cell carcinoma
(HNSCC) from different disease sites, e.g., oral cavity,
pharynx/hypopharynx, larynx [6-16]. Genetic alterations
identified in HNSCC included over-expression of eIF4E
[6,9], TP53 [7,11] and CDKN2A/P16 proteins [7]. Other
alterations reported included promoter hypermethyla-
tion of CDKN2A/P16 [13] and TP53 mutations [12,16].
In addition, promoter hypermethylation of CDKN2A,
CCNAI and DCC was associated with decreased time to
head and neck cancer recurrence [10].
Despite all these studies, genetic alterations identified
to date have not been used clinically in the assessment
of surgical margins, and no study has developed a gene
signature that can accurately predict which patients with
OSCC are at a higher risk of disease recurrence. This
may be due to the lack of studies using high-throughput
analysis of multiple surgical margins and matched
OSCCs to identify deregulated genes with prognostic
value for recurrence. One probable reason for this defi-
cit is that the application of strict inclusion criteria
(tumors of a single anatomical site, with all margins
being histologically negative, and with multiple margins
of adequate RNA quantity and quality for expression
analyses), presents a challenge for obtaining adequate
sample size to develop a prognostic signature that can
predict recurrence in oral carcinoma. We addressed this
challenge through a hypothesis-driven approach, based
on the hypothesis that commonly over-expressed genes
in OSCC and a subset of histologically normal margins
are biomarkers of recurrence. We used meta-analysis of
published microarray studies to help identify such genes
with high confidence, along with global gene expression
analysis of histologically normal margins and their cor-
responding OSCCs in our own study.
Methods
Patients
This work was performed with the approval of the Univer-
sity Health Network Research Ethics Board. All patients
signed their informed consent before sample collection,
and had surgery as their primary treatment. Tissue samples
were prospectively collected at time of surgery from the
Toronto General Hospital, Toronto, Ontario, Canada. The
inclusion criteria of patients were based on primary dis-
ease, tumor site (oral cavity), histology of the primary
tumor (squamous cell carcinoma), and histological status
of surgical resection margins. All patients included in this
study had a final pathology report of histologically normal
resection margins, meaning none of the patients had a
positive margin. An experienced head and neck pathologist
(BP-O) performed histological evaluation of all surgical
margins (frozen section analysis, as per standard of care) to
ensure that they were histologically normal. A section from
each tumor sample (OSCC) was stained with hematoxylin-
eosin, to confirm the presence of at least 80% tumor cells.
The primary tumor, histologically normal margins and a
distant normal oral tissue were collected from each patient,
in both training and validation cohorts. All tissue samples
were snap-frozen in liquid nitrogen until RNA extraction
and gene expression analysis. We collected a total of 232
tissue samples from 54 patients (divided into training and
validation sets), as described below.
Samples used for microarrays (training set)
96 samples (histologically normal margins, OSCC and
adjacent normal oral tissues) from 24 patients were used
for oligonucleotide microarray analysis. Patient clinical
data for the training set are shown in Table 1.
Samples used for quantitative real-time reverse-
transcription PCR (RQ-PCR) (validation set)
136 samples (histologically normal margins, OSCC and
adjacent normal oral tissues) from an independent
cohort of 30 patients were used for RQ-PCR validation
analysis. Patient clinical data for the validation set sam-
ples are shown in Table 2.
RNA Isolation, Microarrays and Validation Experiments
The detailed protocol for RNA isolation and the experi-
mental details for microarrays using the Human Gen-
ome HG-U133A 2.0 plus oligonucleotide arrays
(Affymetrix, Santa Clara, CA, USA), as well as validation
experiments by RQ-PCR are described in Additional file
1, Methods S1.
Bioinformatic Analyses
All bioinformatic analyses of array data were performed
in the R language and environment for statistical com-
puting (version 2.10.0) implemented on CentOS 5.1 on
an IBM HS21 Linux cluster. We pre-processed each
public data set using GCRMA normalization [17] with
updated Entrez Gene-based chip definition files [18],
using the affy R package (version 1.24.2) [19]. Genes
with evidence of tumor-normal differential expression
across all public datasets, with a False Discovery Rate
(FDR) of 0.01 and fold-change ≥ 2, were identified using
the rankprod R package [20]. Gene Ontology enrich-
ment analysis was performed with the GOstats Rp a c k -
age (version 2.12.0) [21]. We also used GOEAST (Go
Enrichment Analysis Software Toolkit) [22] for graphical
representation of GO annotations. Analyses are repro-
ducible using the code (available upon request); data
have been deposited in NCBI’s Gene Expression Omni-
bus [23] and are accessible through GEO series acces-
sion number GSE31056 http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE31056.
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Our goal was to identify a prognostic signature for
recurrence in OSCC, based on the hypothesis that gene
expression deregulation occurring in OSCC would be an
early indicator of recurrence if gene expression changes
are present in a subset of histologically normal surgical
resection margins. We performed gene expression pro-
filing of both resection margins and tumors with the
purpose of (1) identifying over-expressed genes in
tumors as potential markers of recurrence in histologi-
cally normal margins, and (2) finding a subset of those
genes predictive of recurrence. In order to generate a
very high-confidence gene set, we augmented the analy-
sis of our data with a meta-analysis of five published
microarray studies [24-28] to reliably identify a set of
genes significantly deregulated in OSCC compared to
normal oral tissues. These five public data sets were
selected based on the availability of raw microarray data,
as well as for the inclusion of both oral cavity tumors
and either adjacent normal tissues or oral tissues from
healthy individuals. Although data from Pyeon et al. [28]
included HPV positive and HPV negative head and neck
carcinomas from different anatomic sites, we selected
oral carcinomas only, which are mainly negative for
HPV infection, as shown in a recent study performed by
our group [29]. This meta-analysis sample set was com-
posed of a total of 199 samples (141 OSCCs, 38 adjacent
normal tissues and 20 healthy normal tissues) from 141
oral cancer patients and 20 healthy individuals (without
cancer) (Table 3). We pre-processed data from the dif-
ferent array platforms with updated chip definition files,
as described above, to correct outdated probe mapping
information from older platforms. We used a Rank Pro-
duct analysis for the public studies, which considered
only the ranking of genes by differential expression
between pairs of samples within studies [20,30], avoiding
batch and platform-related effects which would occur
from directly combining expression values from the dif-
ferent studies. Genes were selected with evidence of up-
regulation in tumors with a False Discovery Rate (FDR)
of 0.01 and fold-change ≥ 2. We chose to focus on
over-expressed genes only, since histologically normal
margins may contain only a fraction of genetically
altered cells, and the presence of genetically normal
cells would likely make down-regulated genes unreliable
markers. By using the intersection of genes identified
both by meta-analysis and the in-house array training
set, we retained only genes that were reproducibly over-
expressed compared to normal oral tissues from healthy
patients and histologically normal margins. These strict
selection criteria for gene signature candidates, based on
prior hypothesis, helped to reduce the risk of over-fitting
during Cox regression analysis.
Data analysis of in-house microarray study
Microarray results from our study were normalized as
described above, along with normal oral tissue samples
from healthy individuals also assayed by Affymetrix
Table 1 Clinicopathological data, recurrence and
outcome data from 24 OSCC patients (N = 96 samples,
training set)
Variables N (%)
Age (years)
Median (range) 58.5 (37-83)
Gender
Male 15 (62.5)
Female 9 (37.5)
Tobacco use
Yes 16 (67)
No 8 (33)
Alcohol use
Yes 17 (71)
No 7 (29)
Tumor site
Tongue 16 (67)
Floor of mouth 4 (17)
Buccal mucosa 2 (8)
Alveolar 2 (8)
T category
T1-T2 12 (50)
T3-T4 12 (50)
Nodal status
Negative (N0) 12 (50)
Positive (N1, N2b, N2c) 12 (50)
Tumor stage
I, II 7 (29)
III, IV 17 (71)
Tumor grade
Moderately differentiated 18 (75)
Poorly differentiated 6 (25)
Recurrence
Yes 9 (37.5)
No 15 (62.5)
Time to recurrence
Median (range) 32 (1.8-34)
Follow-up
Median (range) 13 (1.7-58.8)
Outcome
Alive with no evidence of disease 13 (55)
Alive with disease 2 (8)
Dead of disease 7 (29)
Dead of other causes 2 (8)
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(downloaded from GEO accession number GSE6791).
Probesets with low expression (75
th percentile below
log2(100)) or low variance (IQR on log2 scale < 0.5)
were filtered [31] as well as the quality control probe
sets. The treat function from LIMMA: Linear Models
for Microarray Analysis (version 3.2.1) [32] was used to
identify genes ≥ 2-fold up-regulated in tumors compared
to margins from our study, with FDR = 0.01. We took
the intersection of genes identified in both the meta-
analysis and in-house microarray experiment, and this
intersection analysis produced a list of 138 genes, which
were used as the feature set for developing the gene sig-
nature for recurrence.
Penalized Cox regression
LASSO penalized Cox regression was used to train a
predictive risk score from the maximum expression of
the 138 genes in any margin of each patient (all these
138 genes being found to be over-expressed in
OSCC). Normalized expression values were first con-
verted to Z-scores for each gene, to ensure equal
effect of the penalty on all coefficients, as is standard
for penalized regression. We applied LASSO penalized
Cox regression as implemented in the penalized R
package (version 0.9-27) [33], to condition a linear
risk score with time to recurrence as the event of
interest. In keeping with the hypothesis that over-
expression of these genes is predictive of recurrence,
we constrained the regression coefficients to positive
values, and selected the L1 penalty parameter by opti-
mizing 10-fold cross-validated likelihood. Since the
cross-validated likelihood depends on the randomized
folding of the data, we repeated the regression 50
times and selected the model with the highest cross-
validated likelihood.
Results
Patient characteristics: OSCC recurrence
As shown in Table 1 and Table 2, 9/24 patients (train-
ing set) and 7/30 patients (independent validation set)
had disease recurrence. Median time to local recurrence
(by Kaplan Meier estimate) of patients in the training
set was 32 months (range 2-34 months). Similarly,
patients from the validation set recurred within 2-36
months. All patients had local recurrence, and some
patients also had regional and/or distant failure (detailed
data in Tables 1 and 2). Median (by reverse Kaplan-
Meier estimate) and range of follow-up times of patients
were 20 months (1.4-57 months) in the training set and
23 months (1-81 months) in the validation set.
Table 2 Clinicopathological data, recurrence data and
outcome data from 30 OSCC patients (N = 136 samples,
validation set)
Variables N (%)
Age (years)
Median (range) 67 (48-81)
Gender
Male 21 (70)
Female 9 (30)
Tobacco use
Yes 25 (83)
No 5 (17)
Alcohol use
Yes 21 (70)
No 9 (30)
Tumor site
Tongue 18 (50)
Floor of mouth 8 (27)
Tongue + Floor of mouth 3 (10)
Buccal mucosa 2 (7)
Alveolar 1 (3)
Retromolar 1 (3)
T category
T1-T2 14 (47)
T3-T4 16 (53)
Nodal status
Negative (N0) 24 (80)
Positive (N1, N2b, N2c) 6 (20)
Tumor stage
I, II 13 (43)
III, IV 17 (57)
Tumor grade
Moderately differentiated 23 (77)
Poorly differentiated 7 (23)
Recurrence
Yes 7 (23)
No 23 (77)
Time to recurrence
Median (range) 8 (2-36)
Follow-up
Median (range) 21 (1-81)
Outcome
Alive with no evidence of disease 23 (77)
Alive with disease 4 (13)
Dead of disease 2 (7)
Dead of other causes 1 (3)
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normal oral tissues
Meta-analysis of the five public data sets (Table 3) iden-
tified 667 up-regulated genes in OSCC; results are pro-
vided in Additional file 2, Table S1. Requiring two-fold
up-regulation in tumors in both the meta-analysis of
public datasets and our microarray experiment, with
FDR < 0.01, identified 138 over-expressed genes (Addi-
tional file 3, Table S2). The expression patterns of these
genes in tumors, margins, and normal oral tissue sam-
ples from healthy individuals are shown as a heatmap in
Figure 1. As seen in the hierarchical clustering, the 138
genes accurately discriminate between the tumors and
margins of the in-house study, as well as normal oral
tissues from a publicly available study (as described in
Methods). We performed LASSO penalized regression
of these 138 genes and selected a total of six genes. Of
these six genes, we retained four genes with the largest
coefficients (MMP1, COL4A1, P4HA2 and THBS2), and
eliminated two genes with very small coefficients (PXDN
and PMEPA1), which together contributed less than 5%
of the magnitude of the risk score. These four genes
constituted a 4-gene signature of recurrence. In the
heatmap, Gene cluster “B” contains three of the four
genes in the signature (COL4A1, P4HA2 and THBS2),
and it shows frequent up-regulation in the surgical mar-
gins compared to the normal oral tissues. Strikingly,
MMP1,f o u n di ng e n ec l u s t e r“A”,s h o w sl e s sf r e q u e n t
over-expression in the margins, but has extreme differ-
ential expression between margins and OSCCs (400-fold
up-regulation as detected by microarrays, and 800-fold
up-regulation, validated by RQ-PCR). The proteins
encoded by the 138 genes are also shown in a protein
interaction network that highlights the most highly
inter-connected proteins (Figure 2 and Additional file 1,
Methods S1). In the heatmap, the main features of clus-
ters A and B are the large number of interacting MMP
proteins in cluster A, which contains MMP1,a n dc o l -
lagens plus TGFB1 in cluster B, which also contains
P4HA2, THBS2 and COL4A1 genes of the signature.
The large number of MMPs and collagen proteins are
closely connected; in particular, MMP9 interacts with
both THBS2 and COL4A1, and indirectly with MMP1.
Results of Gene Ontology (GO) enrichment analysis of
all 138 genes are presented in Additional file 4, Table
S3. Graphical representations of GO annotations are
shown in Additional file 5, GO biological processes,
Additional file 6, GO cellular component and Additional
file 7, GO molecular function.
Over-expressed genes in surgical margins: prognostic
value for recurrence
We examined these 138 genes (see above) for univariate
association with recurrence in the microarray training
data, which, since recurrence was not used in the selec-
tion of these genes, constitutes the first validation of our
study hypothesis. We found significant enrichment for
univariate association with recurrence in these 138
genes (see Additional file 8, Figure S1 for comparison of
the distribution of nominal p-values with a null distribu-
tion empirically determined by permutation of the out-
come labels).
Four-gene prognostic signature for OSCC recurrence
We performed quantitative PCR validation of the 4-gene
signature (MMP1, COL4A1, P4HA2 and THBS2)i na
separate patient cohort (Table 2). This validation analy-
sis confirmed that all four genes were up-regulated in
margins and OSCC samples from patients with disease
recurrence compared to margins and OSCCs from
patients who did not recur (Figure 3A). The risk score
was calculated using the maximum expression in any
margin of each patient, and was dichotomized at the
median score. These risk groups were predictive of
recurrence in an independent test cohort assayed by
RQ-PCR (136 samples; N = 30 patients) (HR = 6.8, p=
0.04, logrank test) (Figure 3B). In multivariate Cox ana-
lysis, correction for T (tumor size) and N (nodal status)
resulted only in a slight increase in significance level of
the four-gene risk score (p=0 . 0 6 , likelihood ratio test).
Table 3 Description of the five publicly available data sets used for meta-analysis
Public Data Set Reference and
Accession ID
Sample Size Array Platform
Toruner et al. 2004
GDS1584
16 oral carcinoma and 4 adjacent normal tissues from 16 patients Human Genome U133A Plus 2.0
(Affymetrix)
Ye et al. 2008
GSE9844
26 oral carcinoma samples and 12 adjacent normal tissues from 26 patients Human Genome U133A Plus 2.0
(Affymetrix)
Kuriakose et al. 2004
GDS2520
22 head and neck carcinomas and 22 adjacent normal tissues from 22
patients
Human Genome U95A
(Affymetrix)
Sticht et al. 2008
GSE10121
35 oral carcinoma samples from 35 patients and 6 normal oral tissues from
healthy individuals
Human Oligo Set 4.0 (Operon)
Pyeon et al., 2007
GSE6791
42 head and neck carcinoma samples from 42 patients and 14 normal oral
tissues from healthy individuals
Human Genome U133A Plus 2.0
(Affymetrix)
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predictive of recurrence in either training or validation
cohorts. The coefficients of the 4-gene risk score, for
use with Z-score scaled expression values, are summar-
ized in Table 4.
In addition, we performed a survival Receiver Operat-
ing Characteristic (ROC) analysis to demonstrate the
sensitivity and specificity of the model in the test set.
This analysis showed the effect of altering the cutoff
threshold between high and low-risk patients. Our
results showed that the use of a very high threshold to
define high-risk patients predicts a majority of recur-
rences at a low false-positive rate (20%). The area under
the ROC curve (AUC) for recurrence within 36 months
was 0.73, an improvement over the expected AUC of
0.5 for unpredictive models (Additional file 9, Figure
S2). While we maintained the standard median cutoff
d u et ot h el i m i t e ds a m p l es i z e ,al a r g e rs t u d yi nt h e
f u t u r em a yb ea b l et of u r t h e rf i n e - t u n et h ec u t o f f
threshold to optimize sensitivity and specificity in the
context of the relative risks that treatment options
informed by this prognostic score entail.
Effect of reducing the number of available margins
S i m u l a t i n gt h es e l e c t i o no fo n l yas i n g l em a r g i nf r o m
each patient, the 4-gene signature maintained a predic-
tive effect in both the training and validation sets (med-
ian HR = 2.2 in the training set and 1.8 in the validation
set, with 82% and 99% of bootstrapped hazard ratios
greater than the no-effect value of HR = 1) (Additional
file 10, Figure S3). Results from the bootstrap simula-
tions showed smaller hazard ratios, compared with
hazard ratios obtained when using the maximum
expression value from several margins. This difference
Figure 1 Heatmap of 138 genes up-regulated in OSCC. Expression values for each row (gene) are scaled to z-scores for visualization. Margins
and tumors annotated with darker colors above the heatmap are from patients who experienced recurrence.
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ber of margins and recurrence in the training set (HR =
1.17, p = 0.69 logrank test) or the validation set (HR =
1.30, p = 0.24 logrank test). However, a plausible expla-
nation for this difference is that increasing the number
of observed margins increases the probability of obser-
ving genetic alterations spreading asymmetrically from
the tumor, since genetic alterations are not seen in all
surgical margins.
Discussion
It is known that histologically normal margins may har-
bor genetic changes also found in the primary tumor, as
shown by studies in HNSCC, including oral carcinomas
[7]. In oral carcinoma, local recurrence may arise from
cancer cells left behind after surgery, undetectable by
histopathology (minimal residual cancer), or from fields
of genetically altered cells with the potential to give rise
to a new carcinoma [34]; such fields precede the tumor
and can be detected in the surrounding mucosa (surgi-
cal resection margins). Molecular changes that are com-
monly detected in margins as well as the corresponding
tumor could indicate that pre-malignant or malignant
clones were able to migrate to the surrounding tissue,
giving rise to a primary tumor recurrence [35].
Herein, we show that global gene expression analysis
of histologically normal margins and OSCC is a valuable
approach for the identification of deregulated genes and
pathways associated with OSCC recurrence. We used a
multi-step procedure including our in-house whole-gen-
ome expression profiling experiment and a meta-analy-
sis of five published microarray datasets to develop a 4-
Figure 2 Protein-protein interaction network of 138 genes. I2D version 1.72 was used to identify protein interactions for the 138 genes
shown in the heatmap. The resulting network was visualized using NAViGaTOR 2.1.14 http://ophid.utoronto.ca/navigator. Color of nodes
corresponds to Gene Ontology biological function, as described in the legend. Red-highlighted squares represent the four genes in the signature
of OSCC recurrence.
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for prediction of recurrence in OSCC. This signature is
based on genes found to be consistently over-expressed
in OSCC as compared to normal oral mucosa; these
genes are also over-expressed in a subset of histologi-
cally normal surgical resection margins, and their over-
expression in such margins provides an indication of the
presence of genetic changes before histological altera-
tions can be detected by histology. Notably, our initial
analyses reveal that this 4-gene signature predicted
recurrence in two of the patients (Pts. 17 and 20, Table
2, validation set) who had not recurred until the latest
update of the clinical data for recurrence status. Both of
these patients had local recurrence, 8 and 19 months
after surgery, respectively.
Genes identified in the 4-gene signature (MMP1,
COL4A1, THBS2 and P4HA2) play major roles in cell-
cell and/or cell-matrix interaction, and invasion. The
direct and indirect partners of these genes are illustrated
in Figure 2. The functions of two genes (P4HA2 and
THBS2) in our signature of OSCC recurrence and their
roles in cancer are not well understood. P4HA2 encodes
a key enzyme involved in collagen synthesis, and its
over-expression has been previously reported in papil-
lary thyroid cancer [36]. THBS2 is a matricellular pro-
tein that encodes an adhesive glycoprotein and interacts
with other proteins to modulate cell-matrix interactions
[37]. Interestingly, THBS2 is associated with tumor
growth in adult mouse tissues [37]. The two other genes
in our OSCC recurrence signature (COL4A1 and
MMP1) are better characterized in cancer. COL4A1
encodes the major type IV alpha collagen chain and is
one of the main components of basement membranes.
Basement membranes have several important biological
roles, and are essential for embryonic development,
proper tissue architecture, and tissue remodeling [38].
COL4A1 binds other collagens (COL4A2, 3, 4, 5 and 6),
as well as LAMC2 (laminin, gamma 2), TGFB1
(B) (A)
Figure 3 Heatmap of validation data and Kaplan-Meier plot of disease recurrence. (A) Unsupervised hierarchical clustering of the
quantitative real-time PCR (validation data) showing the maximum expression levels of MMP1, P4HA2, THBS2 and COL4A1 in margins from
patients with and without recurrence and with a follow-up time ≥ 12 months. Margins annotated with darker green above the heatmap are
from patients who experienced recurrence. Margins from patients with locally recurrent tumors show increased expression levels of the four-
gene signature compared to patients who did not recur. (B) Kaplan-Meier plot of quantitative real-time PCR data for patients in the validation
set. Patients are assigned to high or low risk based on their four-gene signature risk score. As seen in the Kaplan-Meier plot, patients with over-
expression of the 4-gene signature are at high risk for disease recurrence; all patients who experienced recurrence in the validation set are in the
high risk group, suggesting that over-expression of this signature was highly predictive of recurrence in the validation set.
Table 4 Coefficients of the linear risk score for z-score
normalized log2-expression values.
Gene Coefficient FC (microarray) FC (RQ-PCR) p-value (qPCR)
MMP1 0.63 405 798 9E-16
COL4A1 0.25 3.7 4.3 7E-09
P4HA2 0.45 2.7 2.8 1E-06
THBS2 0.34 3 1.9 6E-03
Fold-change (FC) is the geometric-average expression in tumors relative to
surgical resection margins. P-values are for tumor/margin differential
expression in the qPCR (independent validation set) (Wilcoxon Rank Sum test)
Reis et al. BMC Cancer 2011, 11:437
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Page 8 of 11(transforming growth factor, beta 1), among other pro-
teins (Figure 2) http://www.ihop-net.org, playing a rele-
vant role in extracellular matrix-receptor interaction and
focal adhesion [39]. The extracellular matrix undergoes
constant remodeling; during this process, proteins such
as MMP1 can degrade the extracellular matrix proteins
(e.g., collagen IV), and contribute to invasion and metas-
tasis [40]. In cancer, combined over-expression of
COL4A1 and LAMC2 can distinguish OSCC from clini-
cally normal oral cavity/oropharynx tissues [41]; this lat-
ter study suggests that COL4A1 over-expression may be
a useful biomarker for early detection of malignancy.
MMP1 belongs to the family of matrix metallopro-
teases, which are key proteases involved in extracellular
matrix (ECM) degradation [42]. MMP1 encodes a col-
lagenase, which is secreted by tumor cells as well as by
stromal cells stimulated by the tumor; this secreted
enzyme is responsible for breaking down interstitial col-
lagens type I, II and III in normal physiological pro-
cesses (e.g., tissue remodeling) as well as disease
processes (e.g., cancer) [42]. It is believed that the
mechanism of up-regulation of most of the MMPs is
likely due to transcriptional changes, which may occur
following alterations in oncogenes and/or tumor sup-
pressor genes [42]. Indeed, MMP1 has been previously
reported as consistently over-expressed in oral carci-
noma compared to adjacent normal tissues [43-45] and
suggested as a biomarker of malignant transformation in
precursor lesions in oral cancer [44,46,47]. In HNSCC,
over-expression of several genes with roles in invasion
and metastasis, including MMPs, were previously asso-
ciated with treatment failure of HNSCC [48]. In our
study, MMP1 was over-expressed in a subset of margins
exclusively from patients with recurrent OSCC, and
showed the highest fold-change of up-regulation in
OSCC compared to margins. Our results are in agree-
ment with the literature findings of MMP1 over-expres-
sion associated with progression of pre-malignant oral
lesions; in this context, our data showing MMP1 over-
expression in histologically normal surgical margins
from patients who developed local recurrence support
the notion that MMP1 m a yb ei n v o l v e di ni n i t i a ls t e p s
of cellular transformation and tumorigenesis, as well as
invasion of oral carcinoma cells. Indeed, matrix metallo-
proteinases play an important role not only in invasion
and metastasis but also in early stages of cancer devel-
opment/progression [42].
Our data suggest that histologically normal surgical
resection margins that over-express MMP1, COL4A1,
THBS2 and P4HA2 are indicative of an increased risk of
recurrence in OSCC. Patients at higher risk of recur-
rence could potentially benefit from closer disease moni-
toring and/or adjuvant post-operative radiation
treatment, even in the absence of other clinical and
histopathological indicators, such as advanced disease
stage and perineural invasion.
Conclusion
Considering that our 4-gene signature showed prognos-
tic value for recurrence in two independent patient
cohorts, over-expression of this signature may be used
for molecular analysis of histologically negative margins
in oral carcinoma.
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